Iambic has secured over USD 100 million in oversubscribed financing from investors including Alexandria Venture Investments, Illumina Ventures and Regeneron Ventures, following European Society for Medical Oncology (ESMO) congress data for its brain-penetrant HER2 inhibitor IAM1363 showing antitumour activity in wild-type and mutant malignancies. In addition, the AI drug discovery company announced a research collaboration with Jazz Pharmaceuticals evaluating IAM1363 plus bispecific antibody (BsAb) zanidatamab in HER2-positive breast cancer after trastuzumab deruxtecan treatment.

The company founded in 2020 has raised a cumulative USD 300 million including a previous USD 200 million financing, supporting internal development and partnership programmes across oncology and neurological disorders. Chief executive officer Tom Miller highlighted near-term clinical milestones and expanded discovery collaborations leveraging the firm's AI platform for first-in-class and best-in-class candidate identification.

PharmCube's NextBiopharm® database lists 7 projects in Iambic's pipeline, mostly in oncology. Click here to request a free trial for NextBiopharm®.